{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "This Comment discusses how the emerging SARS-CoV-2 variants of concern could impact on the hopes of long-term pandemic control through vaccination and the mutations that might be relevant to the design of modified vaccines."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33927376",
  "DateCompleted": {
    "Year": "2021",
    "Month": "06",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "10",
    "Day": "27"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/s41577-021-00556-5"
    ],
    "Journal": {
      "ISSN": "1474-1741",
      "JournalIssue": {
        "Volume": "21",
        "Issue": "6",
        "PubDate": {
          "Year": "2021",
          "Month": "Jun"
        }
      },
      "Title": "Nature reviews. Immunology",
      "ISOAbbreviation": "Nat Rev Immunol"
    },
    "ArticleTitle": "Will SARS-CoV-2 variants of concern affect the promise of vaccines?",
    "Pagination": {
      "StartPage": "340",
      "EndPage": "341",
      "MedlinePgn": "340-341"
    },
    "Abstract": {
      "AbstractText": [
        "Initial optimism regarding the development of COVID-19 vaccines has been tempered by the emergence of new variants of SARS-CoV-2. Will vaccination be able to contain the pandemic? How can we best optimize the limited supplies of vaccines available and what should future COVID-19 vaccines look like?"
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk."
          }
        ],
        "LastName": "Gupta",
        "ForeName": "Ravindra K",
        "Initials": "RK"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Nat Rev Immunol",
    "NlmUniqueID": "101124169",
    "ISSNLinking": "1474-1733"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "Nat Rev Immunol. 2021 May 10;:",
      "PMID": "33972765"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "immunology",
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "pharmacology",
        "supply & distribution"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Evolution, Molecular"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation Accumulation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neutralization Tests"
    },
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology"
      ],
      "DescriptorName": "Virulence"
    }
  ],
  "CoiStatement": "R.K.G. has received consultancy fees from Janssen related to work on vaccines."
}